SEARCH:   Advanced

Blood, 1 October 2007, Vol. 110, No. 7, pp. 2302-2308. Prepublished online as a Blood First Edition Paper on June 27, 2007; DOI 10.1182/blood-2007-03-078576. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-03-078576v1 110/7/2302    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Soriano, A. O. Articles by Garcia-Manero, G. Search for Related Content PubMed PubMed Citation Articles by Soriano, A. O. Articles by Garcia-Manero, G. Related Collections Neoplasia Chemokines, Cytokines, and Interleukins Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome Andres O. Soriano1, Hui Yang1, Stefan Faderl1, Zeev Estrov1, Francis Giles1, Farhad Ravandi1, Jorge Cortes1, William G. Wierda1, Souzanne Ouzounian1, Andres Quezada1, Sherry Pierce1, Elihu H. Estey1, Jean-Pierre J. Issa1, Hagop M. Kantarjian1, and Guillermo Garcia-Manero1 1 Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX The combination of a DNA hypomethylating agent with a histone deacetylase inhibitor has synergistic antileukemia activity and may restore sensitivity to all-trans retinoic acid (ATRA). We conducted a phase 1/2 study of the combination of 5-azacitidine (5-AZA), valproic acid (VPA), and ATRA in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. 5-AZA was administered subcutaneously at a fixed dose of 75 mg/m2 daily for 7 days. VPA was dose-escalated and given orally daily for 7 days concomitantly with 5-AZA. ATRA was given at 45 mg/m2 orally daily for 5 days, starting on day 3. A total of 53 patients were treated. Their median age was 69 years (range, 5-84 years). The maximum tolerated dose of VPA in this combination was 50 mg/kg daily for 7 days. Dose-limiting toxicity was reversible neurotoxicity. The overall response rate was 42%. In previously untreated older patients, the response rate was 52%. Median number of courses to response was 1 (range, 1-3 courses). Median remission duration was 26 weeks, and median survival has not been reached. A significant decrease in global DNA methylation and induction of histone acetylation were achieved. VPA blood levels were higher in responders (P < .005). In conclusion, the combination studied is safe and has significant clinical activity. This clinical trial was registered at www.clinicaltrials.gov as no. NCT00326170 [ClinicalTrials.gov] . CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. A. Lane and B. A. Chabner Histone Deacetylase Inhibitors in Cancer Therapy J. Clin. Oncol., November 10, 2009; 27(32): 5459 - 5468. [Abstract] [Full Text] [PDF] M. Schaefer, S. Hagemann, K. Hanna, and F. Lyko Azacytidine Inhibits RNA Methylation at DNMT2 Target Sites in Human Cancer Cell Lines Cancer Res., October 15, 2009; 69(20): 8127 - 8132. [Abstract] [Full Text] [PDF] V. Pistoia, C. Cocco, and I. Airoldi Interleukin-12 Receptor {beta}2: From Cytokine Receptor to Gatekeeper Gene in Human B-Cell Malignancies J. Clin. Oncol., October 1, 2009; 27(28): 4809 - 4816. [Abstract] [Full Text] [PDF] T. E. Fandy, J. G. Herman, P. Kerns, A. Jiemjit, E. A. Sugar, S.-H. Choi, A. S. Yang, T. Aucott, T. Dauses, R. Odchimar-Reissig, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies Blood, September 24, 2009; 114(13): 2764 - 2773. [Abstract] [Full Text] [PDF] M. T. Voso, V. Santini, C. Finelli, P. Musto, E. Pogliani, E. Angelucci, G. Fioritoni, G. Alimena, L. Maurillo, A. Cortelezzi, et al. Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes Clin. Cancer Res., August 1, 2009; 15(15): 5002 - 5007. [Abstract] [Full Text] [PDF] J.-P. J. Issa and H. M. Kantarjian Targeting DNA Methylation Clin. Cancer Res., June 15, 2009; 15(12): 3938 - 3946. [Abstract] [Full Text] [PDF] H. M. Prince, M. J. Bishton, and S. J. Harrison Clinical Studies of Histone Deacetylase Inhibitors Clin. Cancer Res., June 15, 2009; 15(12): 3958 - 3969. [Abstract] [Full Text] [PDF] J. Hallas, S. Friis, L. Bjerrum, H. Stovring, S. F. Narverud, T. Heyerdahl, K. Gronbaek, and M. Andersen Cancer Risk in Long-term Users of Valproate: A Population-Based Case-Control Study Cancer Epidemiol. Biomarkers Prev., June 1, 2009; 18(6): 1714 - 1719. [Abstract] [Full Text] [PDF] M. S.Q. Kortenhorst, S. Isharwal, P. J. van Diest, W. H. Chowdhury, C. Marlow, M. A. Carducci, R. Rodriguez, and R. W. Veltri Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo Mol. Cancer Ther., April 1, 2009; 8(4): 802 - 808. [Abstract] [Full Text] [PDF] O. M. Odenike, S. Alkan, D. Sher, J. E. Godwin, D. Huo, S. J. Brandt, M. Green, J. Xie, Y. Zhang, D. H. Vesole, et al. Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia Clin. Cancer Res., November 1, 2008; 14(21): 7095 - 7101. [Abstract] [Full Text] [PDF] J. Laubach and A. V. Rao Current and Emerging Strategies for the Management of Acute Myeloid Leukemia in the Elderly Oncologist, October 1, 2008; 13(10): 1097 - 1108. [Abstract] [Full Text] [PDF] C. Stresemann, I. Bokelmann, U. Mahlknecht, and F. Lyko Azacytidine causes complex DNA methylation responses in myeloid leukemia Mol. Cancer Ther., September 1, 2008; 7(9): 2998 - 3005. [Abstract] [Full Text] [PDF] G. Garcia-Manero, S. Assouline, J. Cortes, Z. Estrov, H. Kantarjian, H. Yang, W. M. Newsome, W. H. Miller Jr, C. Rousseau, A. Kalita, et al. Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia Blood, August 15, 2008; 112(4): 981 - 989. [Abstract] [Full Text] [PDF] B. T. Kawasaki, E. M. Hurt, T. Mistree, and W. L. Farrar Targeting Cancer Stem Cells with Phytochemicals Mol. Interv., August 1, 2008; 8(4): 174 - 184. [Abstract] [Full Text] [PDF] S. D. Nimer Myelodysplastic syndromes Blood, May 15, 2008; 111(10): 4841 - 4851. [Abstract] [Full Text] [PDF] G. Garcia-Manero, H. Yang, C. Bueso-Ramos, A. Ferrajoli, J. Cortes, W. G. Wierda, S. Faderl, C. Koller, G. Morris, G. Rosner, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes Blood, February 1, 2008; 111(3): 1060 - 1066. [Abstract] [Full Text] [PDF] N. Kroger Epigenetic Modulation and Other Options to Improve Outcome of Stem Cell Transplantation in MDS Hematology, January 1, 2008; 2008(1): 60 - 67. [Abstract] [Full Text] [PDF]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020